Summary & Overview
Other Skin, Subcutaneous Tissue and Breast Procedures without CC/MCC: Inpatient Reimbursement Overview
DRG 581 encompasses uncomplicated skin, subcutaneous tissue and breast procedures without Major Complication or Comorbidity or Complication or Comorbidity and defines a lower resource inpatient category. It matters for inpatient reimbursement because it determines the standardized Medicare payment level for these straightforward surgical admissions.
DRG 581 Overview
DRG 581 covers a range of surgical procedures on the skin, subcutaneous tissue and breast when no Major Complication or Comorbidity or Complication or Comorbidity is present, typically including excisions, repairs, debridements and straightforward breast procedures. These cases are generally lower resource intensity compared with those classified with complications, affecting inpatient payment rates under Medicare inpatient prospective payment systems. Accurate assignment ensures hospitals receive the appropriate Diagnosis-Related Group payment for uncomplicated surgical care of these anatomical sites. Understanding the clinical scope and relative resource use is important for reimbursement coding and billing workflows.
Clinical Trials
- Studies evaluating perioperative protocols to reduce surgical site complications after minor to moderate skin, subcutaneous tissue, and breast procedures: randomized or pragmatic trials compare antiseptic agents, closure techniques, antibiotic stewardship strategies, or enhanced intraoperative tissue handling in adult inpatients undergoing excision, flap, or implant-related procedures without major comorbidity. The patient population typically includes adults admitted for elective or urgent procedures coded to this DRG who do not have CC/MCC, and the research question centers on reducing infection, seroma, and reoperation rates during the index hospitalization. Findings are relevant to providers for optimizing clinical pathways and to payers for reducing length of stay and avoidable readmissions and resource use tied to postoperative complications.
- Comparative effectiveness studies of wound-healing technologies and dressing strategies in subcutaneous and breast surgery: prospective cohort or randomized trials compare advanced dressings, negative-pressure wound therapy, or absorbable versus nonabsorbable closures in patients with primary wound closures after oncologic or reconstructive procedures included in this DRG. These studies focus on wound healing time, need for return to OR, pain control, and inpatient nursing resource utilization among relatively low-complexity surgical patients. Payers and hospital administrators benefit from evidence identifying cost-effective products and protocols that shorten inpatient monitoring needs and lower material and readmission costs.
- Post-discharge outcomes and quality-of-life studies assessing functional recovery and healthcare utilization after skin, subcutaneous tissue, and breast procedures: longitudinal observational studies or registry-based analyses track post-discharge complications, outpatient visits, home health use, and patient-reported outcomes in patients assigned to this DRG. The population includes adults discharged after uncomplicated procedures without CC/MCC, with the objective of identifying predictors of delayed recovery or unplanned post-acute care needs. This research informs discharge planning, risk stratification, and bundled-payment models for payers by highlighting drivers of downstream cost and opportunities to target interventions that reduce post-discharge service use.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.